TrialCompass TCL
Back to results
Early Phase 1RecruitingPriority 4 · Lower priorityNCT05838599

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

ClinicalTrials.gov

Plain-language summary

This Early Phase 1 trial is studying Imiquimod and Radiation Therapy for people with cutaneous T-cell lymphoma (skin lymphoma). The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join (key eligibility)

  • Age 18 Years to 90 Years years
  • See full trial listing for complete eligibility

Final eligibility is determined by the trial team. This list is a starting point only.

What's being tested

Imiquimod (DRUG): 5% cream applied topically 5 days/week for 6 weeks | Radiation Therapy (RADIATION): 2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.

Drugs / treatments
Imiquimod, Radiation Therapy
Treatment length
Ask the trial team for details
Visit frequency
Ask the trial team for details
TrialCompass — Clinical Trial Summary

Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides

NCT05838599

Phase: Early Phase 1 | Status: Recruiting | Priority: Lower

Plain-language summary

This Early Phase 1 trial is studying Imiquimod and Radiation Therapy for people with cutaneous T-cell lymphoma (skin lymphoma). The study starts with lower doses to find the safest effective dose before testing in more people. It is available at 1 US location.

Who can join

  • Age 18 Years to 90 Years years
  • See full trial listing for complete eligibility

What's being tested

Imiquimod (DRUG): 5% cream applied topically 5 days/week for 6 weeks | Radiation Therapy (RADIATION): 2 fractions of 4 Gys (total of 8 Gys) starting 1 week after Imiquimoid course over 2 days.

Drugs / treatments: Imiquimod, Radiation Therapy

Treatment length: Ask the trial team for details

Visit frequency: Ask the trial team for details

Trial design

Non-randomized, open-label

Enrollment target: 25 patients

Primary endpoint: Efficacy of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) MF as measured by mSWAT at week 8.; Incidence of treatment-emergent adverse events (safety and tolerability) of a combination local radiotherapy and topical imiquimod approach for the treatment of conventional (CD4+) MF.

Ages: 18 Years to 90 Years

Start date: 2023-07-24 | Est. completion: 2027-12-01

Locations

1 US sites · 1 total

Illinois

Contact

Dermatology Clinical Trials Unit | NUderm-research@northwestern.edu | 312-503-5944

Sponsor: Northwestern University (OTHER)

Tags

CTCL · any

View on ClinicalTrials.gov

https://clinicaltrials.gov/study/NCT05838599

Prepared using TrialCompass (trialcompass.com) on June 19, 2026. For informational purposes only. Always discuss with your healthcare team.